Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Review

Comparative Study

Clinical Trial, Phase III

Clinical Trial, Phase II

Randomized Controlled Trial

Multicenter Study

Publication Year

From

Quick links

Individual year

2020

2019

2018

2013

2010

2008

2006

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Antimitotic Agents""[mesh_terms]

12 Results

Searching titles within these results

Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.

Michel O Steinmetz, Andrea E Prota

Trends in cell biology 2019;28(10):776-792

Full Text

Abstract

Recent Developments on Phenstatins as Potent Antimitotic Agents.

Shi-Meng Wang, Gajjela Bharath Kumar, Grant A L Bare, Jing Leng, Syed Nasir Abbas Bukhari, Hua-Li Qin, Xing Chen

Current medicinal chemistry 2018;25(20):2329-2352

Full Text

Abstract

Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin.

Malini Ravi, Arie Zask, Thomas S Rush

Biochemistry 2006;44(48):15871-9

Full Text

Abstract

Synthesis and Antiproliferative Screening Of Novel Analogs of Regioselectively Demethylated Colchicine and Thiocolchicine.

Dominika Czerwonka, Szymon Sobczak, Ewa Maj, Joanna Wietrzyk, Andrzej Katrusiak, Adam Huczyński

Molecules (Basel, Switzerland) 2020;25(5):1180

Free Full Text

Abstract

In Search of Panacea-Review of Recent Studies Concerning Nature-Derived Anticancer Agents.

Dawid Przystupski, Magdalena J Niemczura, Agata Górska, Stanisław Supplitt, Krzysztof Kotowski, Piotr Wawryka, Paulina Rozborska, Kinga Woźniak, Olga Michel, Aleksander Kiełbik, Weronika Bartosik, Jolanta Saczko, Julita Kulbacka

Nutrients 2020;11(6):1426

Free Full Text

Abstract

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé

Breast cancer (Tokyo, Japan) 2018;25(3):370-374

Free Full Text

Abstract

Crystal structure determination of new antimitotic agent bis(p-fluorobenzyl)trisulfide.

Haoyun An, Xiurong Hu, Jianming Gu, Linshen Chen, Weiming Xu, Xiaopeng Mo, Wanhong Xu, Xiaobo Wang, Xiao Xu

AAPS PharmSciTech 2008;9(2):551-6

Free Full Text

Abstract

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Lot A Devriese, Petronella Els O Witteveen, Jantien Wanders, Kenneth Law, Geoff Edwards, Larisa Reyderman, William Copalu, Fuping Peng, Serena Marchetti, Jos H Beijnen, Alwin D R Huitema, Emile E Voest, Jan H M Schellens

British journal of clinical pharmacology 2013;75(2):507-15

Free Full Text

Abstract

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Vanesa Ortega, Antonio Antón, Isabel Garau, Noemia Afonso, Lourdes Calvo, Yolanda Fernández, María Martínez-García, Esperanza Blanco, Pilar Zamora, Mirta García, José Juan Illarramendi, César Augusto Rodríguez Sánchez, Miguel Sampayo, Elena Aguirre, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac

Clinical breast cancer 2020;19(2):105-112

Full Text

Abstract

The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.

Matteo Magnani, Francesco Ortuso, Simonetta Soro, Stefano Alcaro, Anna Tramontano, Maurizio Botta

The FEBS journal 2006;273(14):3301-10

Free Full Text

Abstract

Chlorhexidine, ethanol, lipopolysaccharide and nicotine do not enhance the cytotoxicity of a calcium hydroxide pulp capping material.

M A Wheater, J Falvo, F Ruiz, M Byars

International endodontic journal 2013;45(11):989-95

Full Text

Abstract

Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity.

Valentina Appierto, Paola Tiberio, Elena Cavadini, Patrizia Casalini, Graziella Cappelletti, Franca Formelli

Molecular cancer therapeutics 2010;8(12):3360-8

Full Text

Abstract

Results: 1 – 12 / 12

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Antimitotic Agents""[mesh_terms]

Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.

Recent Developments on Phenstatins as Potent Antimitotic Agents.

Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin.

Synthesis and Antiproliferative Screening Of Novel Analogs of Regioselectively Demethylated Colchicine and Thiocolchicine.

In Search of Panacea-Review of Recent Studies Concerning Nature-Derived Anticancer Agents.

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Crystal structure determination of new antimitotic agent bis(p-fluorobenzyl)trisulfide.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.

Chlorhexidine, ethanol, lipopolysaccharide and nicotine do not enhance the cytotoxicity of a calcium hydroxide pulp capping material.

Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity.

Results for
""Antimitotic Agents""[mesh_terms]